Literature DB >> 36016862

Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.

Sung Jun Ma1, Lucas M Serra2, Austin J Bartl2, Hye Ri Han2, Fatemeh Fekrmandi1, Austin J Iovoli1, Kavitha M Prezzano1, Gregory M Hermann1, Han Yu3, Anurag K Singh1.   

Abstract

Background: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the survival benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT) following iC remains unclear.
Methods: The National Cancer Database (NCDB) was queried for primary stage III, cT4N0-1M0 LAPC (2004-2015). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used.
Results: Among 872 patients, 738 patients underwent CFRT and 134 patients received SBRT. Median follow-up was 24.3 months and 22.9 months for the CFRT and SBRT cohorts, respectively. The use of SBRT showed improved survival in both the multivariate analysis (HR 0.78, p=0.025) and 120 propensity-matched pairs (median OS 18.1 vs 15.9 months, p=0.004) compared to the CFRT.
Conclusion: This NCDB analysis suggests survival benefit with the use of SBRT versus CFRT following iC for the LAPC.

Entities:  

Keywords:  NCDB; National Cancer Database; Pancreas; SABR; SBRT

Year:  2021        PMID: 36016862      PMCID: PMC9398186          DOI: 10.1017/s1460396921000212

Source DB:  PubMed          Journal:  J Radiother Pract        ISSN: 1460-3969


  31 in total

Review 1.  Biostatistics primer: what a clinician ought to know: subgroup analyses.

Authors:  Helen Barraclough; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.

Authors:  Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

4.  Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.

Authors:  Jae-Sung Kim; Joo Han Lim; Jee Hyun Kim; Seock-Ah Im; Eui Kyu Chie; Jin-Hyeok Hwang; Tae-You Kim; Yung-Jue Bang; Sung Whan Ha; Yong Bum Yoon
Journal:  Cancer Chemother Pharmacol       Date:  2012-07-18       Impact factor: 3.333

5.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Authors:  Christopher H Crane; Gauri R Varadhachary; John S Yordy; Gregg A Staerkel; Milind M Javle; Howard Safran; Waqar Haque; Bridgett D Hobbs; Sunil Krishnan; Jason B Fleming; Prajnan Das; Jeffrey E Lee; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

6.  Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.

Authors:  Jim Zhong; Kirtesh Patel; Jeffrey Switchenko; Richard J Cassidy; William A Hall; Theresa Gillespie; Pretesh R Patel; David Kooby; Jerome Landry
Journal:  Cancer       Date:  2017-05-10       Impact factor: 6.860

7.  Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.

Authors:  Leila T Tchelebi; Eric J Lehrer; Daniel M Trifiletti; Navesh K Sharma; Niraj J Gusani; Christopher H Crane; Nicholas G Zaorsky
Journal:  Cancer       Date:  2020-03-03       Impact factor: 6.860

8.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

9.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

10.  Dose escalation for locally advanced pancreatic cancer: How high can we go?

Authors:  Lauren E Colbert; Neal Rebueno; Shalini Moningi; Sam Beddar; Gabriel O Sawakuchi; Joseph M Herman; Albert C Koong; Prajnan Das; Emma B Holliday; Eugene J Koay; Cullen M Taniguchi
Journal:  Adv Radiat Oncol       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.